Liquid Biopsy in Glioblastoma

Lorian Ronvaux; Matteo RIVA; An Coosemans; Marielle Herzog; Guillaume ROMMELAERE; Nathalie Donis; Lionel D'HONDT; Jonathan Douxfils

doi:10.3390/cancers14143394

Liquid Biopsy in Glioblastoma

Lorian Ronvaux, Matteo RIVA, An Coosemans, Marielle Herzog , Guillaume ROMMELAERE, Nathalie Donis, Lionel D'HONDT, Jonathan Douxfils

Résultats de recherche: Contribution à un journal/une revue › Article de revue › Revue par des pairs

31 Téléchargements (Pure)

Résumé

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

langue originale	Anglais
Numéro d'article	3394
journal	Cancers
Volume	14
Numéro de publication	14
Les DOIs	https://doi.org/10.3390/cancers14143394
Etat de la publication	Publié - 13 juil. 2022

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

Accès au document

10.3390/cancers14143394

cancers_14_03394Version finale publiée, 1,96 MBLicense: CC BY

https://www.mdpi.com/2072-6694/14/14/3394

Autres fichiers et liens

Lien vers la publication sur Scopus

Clinical Pharmacology Research Group
Douxfils, J. (Promoteur), Dogne, J.-M. (Promoteur), Musuamba Tshinanu, F. (Promoteur), Masereel, B. (Promoteur), Wieërs, G. (Promoteur), Haguet, H. (Chercheur), RONVAUX, L. (Chercheur), Donis, N. (Chercheur), Morimont, L. (Chercheur), Evrard, J. (Chercheur), Siriez, R. (Chercheur), Gillot, C. (Chercheur), FAVRESSE, J. (Chercheur), BOUVY, C. (Chercheur), Djokoto, H. (Chercheur), Didembourg, M. (Chercheur), David, C. (Rôle de support), Melchionda, S. (Rôle de support), Maloteau, V. (Technicien), Boucher, A.-Y. (Technicien), Devel, P. (Technicien), Modaffari, E. (Technicien), Vandeputte, M. (Technicien), De Messemaeker, A. (Secrétaire), Decarpentrie, J. (Chercheur), Vassart, J. (Chercheur) & De Groote, A. (Chercheur)
1/04/22 → …
Projet: Axe de recherche
The GLIOMARKERS project : Development of biomarkers for the diagnostic and the prognostic of glioblastoma
Douxfils, J. (Promoteur), RONVAUX, L. (Chercheur), Donis, N. (Chercheur), Maloteau, V. (Technicien) & Decarpentrie, J. (Chercheur)
1/10/21 → …
Projet: Recherche

Contient cette citation

@article{1ae45d9a65c44fc094fb675fcf13bc94,

title = "Liquid Biopsy in Glioblastoma",

abstract = "Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.",

keywords = "biomarkers, circulating microRNAs, circulating nucleosomes, circulating tumor cells, circulating tumor DNA, diagnosis, extracellular vesicles, follow-up, glioblastoma",

author = "Lorian Ronvaux and Matteo RIVA and An Coosemans and Marielle Herzog and Guillaume ROMMELAERE and Nathalie Donis and Lionel D'HONDT and Jonathan Douxfils",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = jul,

day = "13",

doi = "10.3390/cancers14143394",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "14",

}

TY - JOUR

T1 - Liquid Biopsy in Glioblastoma

AU - Ronvaux, Lorian

AU - RIVA, Matteo

AU - Coosemans, An

AU - Herzog , Marielle

AU - ROMMELAERE, Guillaume

AU - Donis, Nathalie

AU - D'HONDT, Lionel

AU - Douxfils, Jonathan

PY - 2022/7/13

Y1 - 2022/7/13

N2 - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

AB - Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

KW - biomarkers

KW - circulating microRNAs

KW - circulating nucleosomes

KW - circulating tumor cells

KW - circulating tumor DNA

KW - diagnosis

KW - extracellular vesicles

KW - follow-up

KW - glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=85136371506&partnerID=8YFLogxK

U2 - 10.3390/cancers14143394

DO - 10.3390/cancers14143394

M3 - Review article

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 14

M1 - 3394

ER -

Liquid Biopsy in Glioblastoma

Résumé

SDG des Nations Unies

Accès au document

Autres fichiers et liens

Empreinte digitale

Projets

Clinical Pharmacology Research Group

The GLIOMARKERS project : Development of biomarkers for the diagnostic and the prognostic of glioblastoma

Contient cette citation